Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: Protocol for a prospective observational study

Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients

14 p | 3 | 2

Advances in liquid biopsy approaches for early detection and monitoring of cancer

3 p | 2 | 2

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers

10 p | 1 | 1

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer

9 p | 12 | 1

Efficient mutation screening for cervical cancers from circulating tumor DNA in blood

10 p | 9 | 1

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: A case report

4 p | 10 | 0